nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2E1—lung cancer	0.344	1	CbGaD
Carbinoxamine—CYP2C19—Gefitinib—lung cancer	0.0309	0.0665	CbGbCtD
Carbinoxamine—CYP2C19—Teniposide—lung cancer	0.03	0.0644	CbGbCtD
Carbinoxamine—CYP2B6—Irinotecan—lung cancer	0.026	0.0559	CbGbCtD
Carbinoxamine—CYP2C9—Gefitinib—lung cancer	0.0257	0.0553	CbGbCtD
Carbinoxamine—CYP2C9—Teniposide—lung cancer	0.0249	0.0536	CbGbCtD
Carbinoxamine—CYP2D6—Gefitinib—lung cancer	0.0235	0.0505	CbGbCtD
Carbinoxamine—CYP2C8—Erlotinib—lung cancer	0.0218	0.0468	CbGbCtD
Carbinoxamine—CYP2B6—Cisplatin—lung cancer	0.0212	0.0455	CbGbCtD
Carbinoxamine—CYP2E1—Etoposide—lung cancer	0.0211	0.0454	CbGbCtD
Carbinoxamine—CYP2C8—Paclitaxel—lung cancer	0.0199	0.0429	CbGbCtD
Carbinoxamine—CYP2D6—Vinorelbine—lung cancer	0.0181	0.0389	CbGbCtD
Carbinoxamine—CYP3A4—Topotecan—lung cancer	0.0163	0.0351	CbGbCtD
Carbinoxamine—CYP2C8—Etoposide—lung cancer	0.0158	0.0339	CbGbCtD
Carbinoxamine—CYP3A4—Gefitinib—lung cancer	0.0149	0.0321	CbGbCtD
Carbinoxamine—CYP3A4—Teniposide—lung cancer	0.0145	0.0312	CbGbCtD
Carbinoxamine—CYP2B6—Doxorubicin—lung cancer	0.0142	0.0305	CbGbCtD
Carbinoxamine—CYP2C9—Paclitaxel—lung cancer	0.0139	0.0299	CbGbCtD
Carbinoxamine—CYP2D6—Erlotinib—lung cancer	0.0139	0.0299	CbGbCtD
Carbinoxamine—CYP3A4—Vinorelbine—lung cancer	0.0115	0.0248	CbGbCtD
Carbinoxamine—CYP2C9—Cisplatin—lung cancer	0.0112	0.0241	CbGbCtD
Carbinoxamine—CYP2D6—Vinblastine—lung cancer	0.0112	0.024	CbGbCtD
Carbinoxamine—CYP3A4—Crizotinib—lung cancer	0.00916	0.0197	CbGbCtD
Carbinoxamine—CYP3A4—Erlotinib—lung cancer	0.00884	0.019	CbGbCtD
Carbinoxamine—CYP3A4—Paclitaxel—lung cancer	0.00809	0.0174	CbGbCtD
Carbinoxamine—CYP3A4—Irinotecan—lung cancer	0.00798	0.0172	CbGbCtD
Carbinoxamine—CYP3A4—Vinblastine—lung cancer	0.00709	0.0153	CbGbCtD
Carbinoxamine—CYP2D6—Doxorubicin—lung cancer	0.00686	0.0147	CbGbCtD
Carbinoxamine—CYP3A4—Etoposide—lung cancer	0.00639	0.0137	CbGbCtD
Carbinoxamine—CYP3A4—Docetaxel—lung cancer	0.00585	0.0126	CbGbCtD
Carbinoxamine—CYP3A4—Doxorubicin—lung cancer	0.00436	0.00937	CbGbCtD
Carbinoxamine—Insomnia—Erlotinib—lung cancer	0.000317	0.0031	CcSEcCtD
Carbinoxamine—Decreased appetite—Vinblastine—lung cancer	0.000317	0.0031	CcSEcCtD
Carbinoxamine—Chills—Irinotecan—lung cancer	0.000316	0.00308	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Paclitaxel—lung cancer	0.000314	0.00306	CcSEcCtD
Carbinoxamine—Constipation—Vinblastine—lung cancer	0.000312	0.00305	CcSEcCtD
Carbinoxamine—Dyspepsia—Topotecan—lung cancer	0.000312	0.00305	CcSEcCtD
Carbinoxamine—Dyspepsia—Erlotinib—lung cancer	0.000309	0.00301	CcSEcCtD
Carbinoxamine—Decreased appetite—Topotecan—lung cancer	0.000308	0.00301	CcSEcCtD
Carbinoxamine—Chills—Gemcitabine—lung cancer	0.000308	0.003	CcSEcCtD
Carbinoxamine—Fatigue—Topotecan—lung cancer	0.000306	0.00298	CcSEcCtD
Carbinoxamine—Decreased appetite—Erlotinib—lung cancer	0.000305	0.00298	CcSEcCtD
Carbinoxamine—Agranulocytosis—Etoposide—lung cancer	0.000305	0.00297	CcSEcCtD
Carbinoxamine—Vomiting—Teniposide—lung cancer	0.000304	0.00297	CcSEcCtD
Carbinoxamine—Constipation—Topotecan—lung cancer	0.000303	0.00296	CcSEcCtD
Carbinoxamine—Fatigue—Erlotinib—lung cancer	0.000303	0.00295	CcSEcCtD
Carbinoxamine—Feeling abnormal—Vinblastine—lung cancer	0.000301	0.00293	CcSEcCtD
Carbinoxamine—Constipation—Erlotinib—lung cancer	0.0003	0.00293	CcSEcCtD
Carbinoxamine—Headache—Teniposide—lung cancer	0.0003	0.00292	CcSEcCtD
Carbinoxamine—Tinnitus—Cisplatin—lung cancer	0.000298	0.00291	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Vinorelbine—lung cancer	0.000297	0.0029	CcSEcCtD
Carbinoxamine—Tachycardia—Vinorelbine—lung cancer	0.000296	0.00289	CcSEcCtD
Carbinoxamine—Feeling abnormal—Topotecan—lung cancer	0.000292	0.00285	CcSEcCtD
Carbinoxamine—Anorexia—Vinorelbine—lung cancer	0.000289	0.00282	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—lung cancer	0.000289	0.00282	CcSEcCtD
Carbinoxamine—Nausea—Teniposide—lung cancer	0.000284	0.00277	CcSEcCtD
Carbinoxamine—Hypotension—Vinorelbine—lung cancer	0.000284	0.00277	CcSEcCtD
Carbinoxamine—Urticaria—Topotecan—lung cancer	0.000282	0.00275	CcSEcCtD
Carbinoxamine—Vertigo—Irinotecan—lung cancer	0.000276	0.00269	CcSEcCtD
Carbinoxamine—Paraesthesia—Vinorelbine—lung cancer	0.000272	0.00266	CcSEcCtD
Carbinoxamine—Tinnitus—Paclitaxel—lung cancer	0.000268	0.00261	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Docetaxel—lung cancer	0.000266	0.00259	CcSEcCtD
Carbinoxamine—Decreased appetite—Vinorelbine—lung cancer	0.000264	0.00257	CcSEcCtD
Carbinoxamine—Chills—Etoposide—lung cancer	0.000263	0.00256	CcSEcCtD
Carbinoxamine—Vision blurred—Cisplatin—lung cancer	0.000262	0.00256	CcSEcCtD
Carbinoxamine—Asthenia—Vinblastine—lung cancer	0.000262	0.00256	CcSEcCtD
Carbinoxamine—Fatigue—Vinorelbine—lung cancer	0.000262	0.00255	CcSEcCtD
Carbinoxamine—Tremor—Cisplatin—lung cancer	0.000261	0.00254	CcSEcCtD
Carbinoxamine—Constipation—Vinorelbine—lung cancer	0.000259	0.00253	CcSEcCtD
Carbinoxamine—Chills—Paclitaxel—lung cancer	0.000258	0.00251	CcSEcCtD
Carbinoxamine—Asthenia—Topotecan—lung cancer	0.000255	0.00248	CcSEcCtD
Carbinoxamine—Agranulocytosis—Docetaxel—lung cancer	0.000253	0.00247	CcSEcCtD
Carbinoxamine—Confusional state—Irinotecan—lung cancer	0.000252	0.00246	CcSEcCtD
Carbinoxamine—Asthenia—Erlotinib—lung cancer	0.000252	0.00246	CcSEcCtD
Carbinoxamine—Photosensitivity—Doxorubicin—lung cancer	0.00025	0.00244	CcSEcCtD
Carbinoxamine—Feeling abnormal—Vinorelbine—lung cancer	0.00025	0.00244	CcSEcCtD
Carbinoxamine—Diarrhoea—Vinblastine—lung cancer	0.00025	0.00244	CcSEcCtD
Carbinoxamine—Tension—Paclitaxel—lung cancer	0.000245	0.00239	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Irinotecan—lung cancer	0.000245	0.00239	CcSEcCtD
Carbinoxamine—Nervousness—Paclitaxel—lung cancer	0.000243	0.00237	CcSEcCtD
Carbinoxamine—Diarrhoea—Topotecan—lung cancer	0.000243	0.00237	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—lung cancer	0.000242	0.00236	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Irinotecan—lung cancer	0.000242	0.00236	CcSEcCtD
Carbinoxamine—Dizziness—Vinblastine—lung cancer	0.000241	0.00236	CcSEcCtD
Carbinoxamine—Convulsion—Cisplatin—lung cancer	0.000241	0.00235	CcSEcCtD
Carbinoxamine—Urticaria—Vinorelbine—lung cancer	0.000241	0.00235	CcSEcCtD
Carbinoxamine—Diarrhoea—Erlotinib—lung cancer	0.00024	0.00234	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Gemcitabine—lung cancer	0.000239	0.00233	CcSEcCtD
Carbinoxamine—Anorexia—Irinotecan—lung cancer	0.000239	0.00233	CcSEcCtD
Carbinoxamine—Vision blurred—Paclitaxel—lung cancer	0.000236	0.0023	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Gemcitabine—lung cancer	0.000236	0.0023	CcSEcCtD
Carbinoxamine—Dizziness—Topotecan—lung cancer	0.000235	0.00229	CcSEcCtD
Carbinoxamine—Tremor—Paclitaxel—lung cancer	0.000234	0.00229	CcSEcCtD
Carbinoxamine—Hypotension—Irinotecan—lung cancer	0.000234	0.00228	CcSEcCtD
Carbinoxamine—Anorexia—Gemcitabine—lung cancer	0.000232	0.00227	CcSEcCtD
Carbinoxamine—Vomiting—Vinblastine—lung cancer	0.000232	0.00226	CcSEcCtD
Carbinoxamine—Dizziness—Erlotinib—lung cancer	0.000232	0.00226	CcSEcCtD
Carbinoxamine—Agitation—Paclitaxel—lung cancer	0.00023	0.00224	CcSEcCtD
Carbinoxamine—Vertigo—Etoposide—lung cancer	0.000229	0.00224	CcSEcCtD
Carbinoxamine—Headache—Vinblastine—lung cancer	0.000229	0.00223	CcSEcCtD
Carbinoxamine—Hypotension—Gemcitabine—lung cancer	0.000228	0.00222	CcSEcCtD
Carbinoxamine—Insomnia—Irinotecan—lung cancer	0.000226	0.00221	CcSEcCtD
Carbinoxamine—Vomiting—Topotecan—lung cancer	0.000226	0.0022	CcSEcCtD
Carbinoxamine—Paraesthesia—Irinotecan—lung cancer	0.000225	0.00219	CcSEcCtD
Carbinoxamine—Vertigo—Paclitaxel—lung cancer	0.000225	0.00219	CcSEcCtD
Carbinoxamine—Vomiting—Erlotinib—lung cancer	0.000223	0.00218	CcSEcCtD
Carbinoxamine—Somnolence—Irinotecan—lung cancer	0.000222	0.00217	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Cisplatin—lung cancer	0.000222	0.00217	CcSEcCtD
Carbinoxamine—Headache—Topotecan—lung cancer	0.000222	0.00217	CcSEcCtD
Carbinoxamine—Tachycardia—Cisplatin—lung cancer	0.000222	0.00216	CcSEcCtD
Carbinoxamine—Palpitations—Paclitaxel—lung cancer	0.000221	0.00216	CcSEcCtD
Carbinoxamine—Convulsion—Etoposide—lung cancer	0.000221	0.00216	CcSEcCtD
Carbinoxamine—Insomnia—Gemcitabine—lung cancer	0.00022	0.00215	CcSEcCtD
Carbinoxamine—Dyspepsia—Irinotecan—lung cancer	0.00022	0.00215	CcSEcCtD
Carbinoxamine—Headache—Erlotinib—lung cancer	0.00022	0.00214	CcSEcCtD
Carbinoxamine—Diplopia—Doxorubicin—lung cancer	0.00022	0.00214	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Cisplatin—lung cancer	0.00022	0.00214	CcSEcCtD
Carbinoxamine—Paraesthesia—Gemcitabine—lung cancer	0.000219	0.00213	CcSEcCtD
Carbinoxamine—Chills—Docetaxel—lung cancer	0.000218	0.00213	CcSEcCtD
Carbinoxamine—Asthenia—Vinorelbine—lung cancer	0.000218	0.00212	CcSEcCtD
Carbinoxamine—Decreased appetite—Irinotecan—lung cancer	0.000218	0.00212	CcSEcCtD
Carbinoxamine—Nausea—Vinblastine—lung cancer	0.000217	0.00212	CcSEcCtD
Carbinoxamine—Somnolence—Gemcitabine—lung cancer	0.000217	0.00211	CcSEcCtD
Carbinoxamine—Convulsion—Paclitaxel—lung cancer	0.000217	0.00211	CcSEcCtD
Carbinoxamine—Anorexia—Cisplatin—lung cancer	0.000217	0.00211	CcSEcCtD
Carbinoxamine—Fatigue—Irinotecan—lung cancer	0.000216	0.0021	CcSEcCtD
Carbinoxamine—Constipation—Irinotecan—lung cancer	0.000214	0.00209	CcSEcCtD
Carbinoxamine—Hypotension—Cisplatin—lung cancer	0.000212	0.00207	CcSEcCtD
Carbinoxamine—Decreased appetite—Gemcitabine—lung cancer	0.000212	0.00207	CcSEcCtD
Carbinoxamine—Nausea—Topotecan—lung cancer	0.000211	0.00206	CcSEcCtD
Carbinoxamine—Fatigue—Gemcitabine—lung cancer	0.00021	0.00205	CcSEcCtD
Carbinoxamine—Confusional state—Etoposide—lung cancer	0.00021	0.00205	CcSEcCtD
Carbinoxamine—Constipation—Gemcitabine—lung cancer	0.000208	0.00203	CcSEcCtD
Carbinoxamine—Nausea—Erlotinib—lung cancer	0.000208	0.00203	CcSEcCtD
Carbinoxamine—Diarrhoea—Vinorelbine—lung cancer	0.000208	0.00202	CcSEcCtD
Carbinoxamine—Feeling abnormal—Irinotecan—lung cancer	0.000206	0.00201	CcSEcCtD
Carbinoxamine—Confusional state—Paclitaxel—lung cancer	0.000206	0.00201	CcSEcCtD
Carbinoxamine—Paraesthesia—Cisplatin—lung cancer	0.000204	0.00199	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Etoposide—lung cancer	0.000204	0.00199	CcSEcCtD
Carbinoxamine—Tachycardia—Etoposide—lung cancer	0.000203	0.00198	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Etoposide—lung cancer	0.000201	0.00196	CcSEcCtD
Carbinoxamine—Feeling abnormal—Gemcitabine—lung cancer	0.000201	0.00196	CcSEcCtD
Carbinoxamine—Dizziness—Vinorelbine—lung cancer	0.000201	0.00196	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—lung cancer	0.0002	0.00195	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Paclitaxel—lung cancer	0.0002	0.00195	CcSEcCtD
Carbinoxamine—Tachycardia—Paclitaxel—lung cancer	0.000199	0.00194	CcSEcCtD
Carbinoxamine—Anorexia—Etoposide—lung cancer	0.000198	0.00194	CcSEcCtD
Carbinoxamine—Decreased appetite—Cisplatin—lung cancer	0.000198	0.00193	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Paclitaxel—lung cancer	0.000197	0.00192	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—lung cancer	0.000196	0.00191	CcSEcCtD
Carbinoxamine—Anorexia—Paclitaxel—lung cancer	0.000195	0.0019	CcSEcCtD
Carbinoxamine—Hypotension—Etoposide—lung cancer	0.000195	0.0019	CcSEcCtD
Carbinoxamine—Vomiting—Vinorelbine—lung cancer	0.000193	0.00188	CcSEcCtD
Carbinoxamine—Hypotension—Paclitaxel—lung cancer	0.000191	0.00186	CcSEcCtD
Carbinoxamine—Headache—Vinorelbine—lung cancer	0.00019	0.00185	CcSEcCtD
Carbinoxamine—Palpitations—Docetaxel—lung cancer	0.000187	0.00183	CcSEcCtD
Carbinoxamine—Feeling abnormal—Cisplatin—lung cancer	0.000187	0.00183	CcSEcCtD
Carbinoxamine—Paraesthesia—Etoposide—lung cancer	0.000187	0.00182	CcSEcCtD
Carbinoxamine—Somnolence—Etoposide—lung cancer	0.000185	0.0018	CcSEcCtD
Carbinoxamine—Insomnia—Paclitaxel—lung cancer	0.000185	0.0018	CcSEcCtD
Carbinoxamine—Clomipramine—GSTP1—lung cancer	0.000184	0.272	CrCbGaD
Carbinoxamine—Convulsion—Docetaxel—lung cancer	0.000184	0.00179	CcSEcCtD
Carbinoxamine—Paraesthesia—Paclitaxel—lung cancer	0.000183	0.00179	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—lung cancer	0.000182	0.00178	CcSEcCtD
Carbinoxamine—Somnolence—Paclitaxel—lung cancer	0.000181	0.00177	CcSEcCtD
Carbinoxamine—Decreased appetite—Etoposide—lung cancer	0.000181	0.00176	CcSEcCtD
Carbinoxamine—Nausea—Vinorelbine—lung cancer	0.00018	0.00176	CcSEcCtD
Carbinoxamine—Dyspepsia—Paclitaxel—lung cancer	0.00018	0.00175	CcSEcCtD
Carbinoxamine—Asthenia—Irinotecan—lung cancer	0.00018	0.00175	CcSEcCtD
Carbinoxamine—Fatigue—Etoposide—lung cancer	0.000179	0.00175	CcSEcCtD
Carbinoxamine—Constipation—Etoposide—lung cancer	0.000178	0.00174	CcSEcCtD
Carbinoxamine—Decreased appetite—Paclitaxel—lung cancer	0.000177	0.00173	CcSEcCtD
Carbinoxamine—Fatigue—Paclitaxel—lung cancer	0.000176	0.00172	CcSEcCtD
Carbinoxamine—Pollakiuria—Doxorubicin—lung cancer	0.000175	0.00171	CcSEcCtD
Carbinoxamine—Asthenia—Gemcitabine—lung cancer	0.000175	0.00171	CcSEcCtD
Carbinoxamine—Constipation—Paclitaxel—lung cancer	0.000175	0.0017	CcSEcCtD
Carbinoxamine—Confusional state—Docetaxel—lung cancer	0.000174	0.0017	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Doxorubicin—lung cancer	0.000173	0.00169	CcSEcCtD
Carbinoxamine—Feeling abnormal—Etoposide—lung cancer	0.000172	0.00167	CcSEcCtD
Carbinoxamine—Diarrhoea—Irinotecan—lung cancer	0.000171	0.00167	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Docetaxel—lung cancer	0.000169	0.00165	CcSEcCtD
Carbinoxamine—Drowsiness—Doxorubicin—lung cancer	0.000169	0.00165	CcSEcCtD
Carbinoxamine—Tachycardia—Docetaxel—lung cancer	0.000169	0.00165	CcSEcCtD
Carbinoxamine—Feeling abnormal—Paclitaxel—lung cancer	0.000168	0.00164	CcSEcCtD
Carbinoxamine—Diarrhoea—Gemcitabine—lung cancer	0.000167	0.00163	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Doxorubicin—lung cancer	0.000166	0.00162	CcSEcCtD
Carbinoxamine—Dizziness—Irinotecan—lung cancer	0.000165	0.00161	CcSEcCtD
Carbinoxamine—Urticaria—Etoposide—lung cancer	0.000165	0.00161	CcSEcCtD
Carbinoxamine—Anorexia—Docetaxel—lung cancer	0.000165	0.00161	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—lung cancer	0.000164	0.0016	CcSEcCtD
Carbinoxamine—Asthenia—Cisplatin—lung cancer	0.000163	0.00159	CcSEcCtD
Carbinoxamine—Urticaria—Paclitaxel—lung cancer	0.000162	0.00158	CcSEcCtD
Carbinoxamine—Hypotension—Docetaxel—lung cancer	0.000162	0.00158	CcSEcCtD
Carbinoxamine—Vomiting—Irinotecan—lung cancer	0.000159	0.00155	CcSEcCtD
Carbinoxamine—Agranulocytosis—Doxorubicin—lung cancer	0.000158	0.00154	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—lung cancer	0.000157	0.00154	CcSEcCtD
Carbinoxamine—Headache—Irinotecan—lung cancer	0.000157	0.00153	CcSEcCtD
Carbinoxamine—Insomnia—Docetaxel—lung cancer	0.000156	0.00153	CcSEcCtD
Carbinoxamine—Diarrhoea—Cisplatin—lung cancer	0.000155	0.00152	CcSEcCtD
Carbinoxamine—Paraesthesia—Docetaxel—lung cancer	0.000155	0.00152	CcSEcCtD
Carbinoxamine—Vomiting—Gemcitabine—lung cancer	0.000155	0.00151	CcSEcCtD
Carbinoxamine—Somnolence—Docetaxel—lung cancer	0.000154	0.0015	CcSEcCtD
Carbinoxamine—Headache—Gemcitabine—lung cancer	0.000153	0.00149	CcSEcCtD
Carbinoxamine—Dyspepsia—Docetaxel—lung cancer	0.000152	0.00149	CcSEcCtD
Carbinoxamine—Decreased appetite—Docetaxel—lung cancer	0.00015	0.00147	CcSEcCtD
Carbinoxamine—Asthenia—Etoposide—lung cancer	0.000149	0.00146	CcSEcCtD
Carbinoxamine—Fatigue—Docetaxel—lung cancer	0.000149	0.00145	CcSEcCtD
Carbinoxamine—Nausea—Irinotecan—lung cancer	0.000149	0.00145	CcSEcCtD
Carbinoxamine—Constipation—Docetaxel—lung cancer	0.000148	0.00144	CcSEcCtD
Carbinoxamine—Asthenia—Paclitaxel—lung cancer	0.000146	0.00143	CcSEcCtD
Carbinoxamine—Nausea—Gemcitabine—lung cancer	0.000145	0.00141	CcSEcCtD
Carbinoxamine—Vomiting—Cisplatin—lung cancer	0.000144	0.00141	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—lung cancer	0.000144	0.0014	CcSEcCtD
Carbinoxamine—Feeling abnormal—Docetaxel—lung cancer	0.000143	0.00139	CcSEcCtD
Carbinoxamine—Diarrhoea—Etoposide—lung cancer	0.000142	0.00139	CcSEcCtD
Carbinoxamine—Tinnitus—Doxorubicin—lung cancer	0.000142	0.00138	CcSEcCtD
Carbinoxamine—Diarrhoea—Paclitaxel—lung cancer	0.00014	0.00136	CcSEcCtD
Carbinoxamine—Dizziness—Etoposide—lung cancer	0.000138	0.00134	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—lung cancer	0.000137	0.00134	CcSEcCtD
Carbinoxamine—Chills—Doxorubicin—lung cancer	0.000136	0.00133	CcSEcCtD
Carbinoxamine—Dizziness—Paclitaxel—lung cancer	0.000135	0.00132	CcSEcCtD
Carbinoxamine—Nausea—Cisplatin—lung cancer	0.000135	0.00132	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—lung cancer	0.000132	0.00129	CcSEcCtD
Carbinoxamine—Vomiting—Etoposide—lung cancer	0.000132	0.00129	CcSEcCtD
Carbinoxamine—Headache—Etoposide—lung cancer	0.00013	0.00127	CcSEcCtD
Carbinoxamine—Tension—Doxorubicin—lung cancer	0.00013	0.00127	CcSEcCtD
Carbinoxamine—Vomiting—Paclitaxel—lung cancer	0.00013	0.00127	CcSEcCtD
Carbinoxamine—Nervousness—Doxorubicin—lung cancer	0.000128	0.00125	CcSEcCtD
Carbinoxamine—Brompheniramine—CYP2E1—lung cancer	0.000128	0.189	CrCbGaD
Carbinoxamine—Headache—Paclitaxel—lung cancer	0.000128	0.00125	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—lung cancer	0.000126	0.00123	CcSEcCtD
Carbinoxamine—Vision blurred—Doxorubicin—lung cancer	0.000125	0.00122	CcSEcCtD
Carbinoxamine—Asthenia—Docetaxel—lung cancer	0.000124	0.00121	CcSEcCtD
Carbinoxamine—Nausea—Etoposide—lung cancer	0.000124	0.00121	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—lung cancer	0.000122	0.00119	CcSEcCtD
Carbinoxamine—Agitation—Doxorubicin—lung cancer	0.000122	0.00119	CcSEcCtD
Carbinoxamine—Nausea—Paclitaxel—lung cancer	0.000121	0.00118	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—lung cancer	0.000121	0.00118	CcSEcCtD
Carbinoxamine—Vertigo—Doxorubicin—lung cancer	0.000119	0.00116	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—lung cancer	0.000119	0.00116	CcSEcCtD
Carbinoxamine—Diarrhoea—Docetaxel—lung cancer	0.000118	0.00115	CcSEcCtD
Carbinoxamine—Palpitations—Doxorubicin—lung cancer	0.000117	0.00114	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—lung cancer	0.000117	0.00114	CcSEcCtD
Carbinoxamine—Convulsion—Doxorubicin—lung cancer	0.000115	0.00112	CcSEcCtD
Carbinoxamine—Dizziness—Docetaxel—lung cancer	0.000114	0.00112	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—lung cancer	0.000113	0.0011	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—lung cancer	0.000112	0.00109	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—lung cancer	0.000111	0.00108	CcSEcCtD
Carbinoxamine—Vomiting—Docetaxel—lung cancer	0.00011	0.00107	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—lung cancer	0.00011	0.00107	CcSEcCtD
Carbinoxamine—Confusional state—Doxorubicin—lung cancer	0.000109	0.00106	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—lung cancer	0.000108	0.00106	CcSEcCtD
Carbinoxamine—Headache—Docetaxel—lung cancer	0.000108	0.00106	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—lung cancer	0.000108	0.00105	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Doxorubicin—lung cancer	0.000106	0.00103	CcSEcCtD
Carbinoxamine—Tachycardia—Doxorubicin—lung cancer	0.000105	0.00103	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Doxorubicin—lung cancer	0.000104	0.00102	CcSEcCtD
Carbinoxamine—Anorexia—Doxorubicin—lung cancer	0.000103	0.001	CcSEcCtD
Carbinoxamine—Nausea—Docetaxel—lung cancer	0.000103	0.001	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—lung cancer	0.000103	0.001	CcSEcCtD
Carbinoxamine—Hypotension—Doxorubicin—lung cancer	0.000101	0.000984	CcSEcCtD
Carbinoxamine—Urticaria—Methotrexate—lung cancer	9.91e-05	0.000966	CcSEcCtD
Carbinoxamine—Insomnia—Doxorubicin—lung cancer	9.77e-05	0.000952	CcSEcCtD
Carbinoxamine—Paraesthesia—Doxorubicin—lung cancer	9.7e-05	0.000946	CcSEcCtD
Carbinoxamine—Somnolence—Doxorubicin—lung cancer	9.6e-05	0.000936	CcSEcCtD
Carbinoxamine—Dyspepsia—Doxorubicin—lung cancer	9.5e-05	0.000927	CcSEcCtD
Carbinoxamine—Decreased appetite—Doxorubicin—lung cancer	9.39e-05	0.000915	CcSEcCtD
Carbinoxamine—Fatigue—Doxorubicin—lung cancer	9.31e-05	0.000908	CcSEcCtD
Carbinoxamine—Constipation—Doxorubicin—lung cancer	9.23e-05	0.0009	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—lung cancer	8.95e-05	0.000873	CcSEcCtD
Carbinoxamine—Feeling abnormal—Doxorubicin—lung cancer	8.9e-05	0.000868	CcSEcCtD
Carbinoxamine—Urticaria—Doxorubicin—lung cancer	8.58e-05	0.000837	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—lung cancer	8.53e-05	0.000832	CcSEcCtD
Carbinoxamine—Dizziness—Methotrexate—lung cancer	8.25e-05	0.000804	CcSEcCtD
Carbinoxamine—Orphenadrine—CYP2E1—lung cancer	8.08e-05	0.119	CrCbGaD
Carbinoxamine—Vomiting—Methotrexate—lung cancer	7.93e-05	0.000773	CcSEcCtD
Carbinoxamine—Headache—Methotrexate—lung cancer	7.81e-05	0.000762	CcSEcCtD
Carbinoxamine—Asthenia—Doxorubicin—lung cancer	7.75e-05	0.000756	CcSEcCtD
Carbinoxamine—Nausea—Methotrexate—lung cancer	7.41e-05	0.000722	CcSEcCtD
Carbinoxamine—Diarrhoea—Doxorubicin—lung cancer	7.39e-05	0.00072	CcSEcCtD
Carbinoxamine—Dizziness—Doxorubicin—lung cancer	7.14e-05	0.000696	CcSEcCtD
Carbinoxamine—Vomiting—Doxorubicin—lung cancer	6.86e-05	0.00067	CcSEcCtD
Carbinoxamine—Headache—Doxorubicin—lung cancer	6.76e-05	0.00066	CcSEcCtD
Carbinoxamine—Chlorpromazine—CYP2E1—lung cancer	6.48e-05	0.0955	CrCbGaD
Carbinoxamine—Nausea—Doxorubicin—lung cancer	6.41e-05	0.000625	CcSEcCtD
Carbinoxamine—Clomipramine—ALB—lung cancer	5.19e-05	0.0765	CrCbGaD
Carbinoxamine—Clomipramine—ABCB1—lung cancer	4.95e-05	0.073	CrCbGaD
Carbinoxamine—Chlorprothixene—ABCB1—lung cancer	4.93e-05	0.0727	CrCbGaD
Carbinoxamine—Chlorpromazine—ALB—lung cancer	3.56e-05	0.0525	CrCbGaD
Carbinoxamine—Chlorpromazine—ABCB1—lung cancer	3.4e-05	0.0501	CrCbGaD
Carbinoxamine—CYP2D6—Metabolism—GCLC—lung cancer	9.31e-06	0.000106	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP2A6—lung cancer	9.31e-06	0.000106	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	9.25e-06	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GCLC—lung cancer	9.23e-06	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP2A6—lung cancer	9.23e-06	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GSTP1—lung cancer	9.2e-06	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	9.2e-06	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CAT—lung cancer	9.14e-06	0.000104	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—AVP—lung cancer	8.98e-06	0.000102	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—PIK3CB—lung cancer	8.96e-06	0.000102	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CAT—lung cancer	8.95e-06	0.000102	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ABCB1—lung cancer	8.89e-06	0.000101	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ENO1—lung cancer	8.83e-06	0.0001	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—B4GALT5—lung cancer	8.78e-06	9.98e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ENO1—lung cancer	8.75e-06	9.95e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—TYMS—lung cancer	8.73e-06	9.93e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	8.72e-06	9.91e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ABCB1—lung cancer	8.71e-06	9.9e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IGF1R—lung cancer	8.65e-06	9.83e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GSTM1—lung cancer	8.63e-06	9.81e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP2E1—lung cancer	8.61e-06	9.78e-05	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CXCL8—lung cancer	8.61e-06	9.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	8.61e-06	9.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—STK11—lung cancer	8.6e-06	9.77e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—TYMS—lung cancer	8.55e-06	9.72e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTA4—lung cancer	8.54e-06	9.71e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NQO1—lung cancer	8.51e-06	9.67e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HES1—lung cancer	8.49e-06	9.65e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GSTM1—lung cancer	8.46e-06	9.61e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	8.33e-06	9.47e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—RAF1—lung cancer	8.33e-06	9.47e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTA2—lung cancer	8.33e-06	9.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	8.26e-06	9.39e-05	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—IL2—lung cancer	8.23e-06	9.35e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CYP1A1—lung cancer	8.18e-06	9.3e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—PIK3CB—lung cancer	8.13e-06	9.24e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ERCC2—lung cancer	8.12e-06	9.23e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	8.07e-06	9.17e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTA1—lung cancer	8.03e-06	9.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CYP1A1—lung cancer	8.02e-06	9.11e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTP1—lung cancer	7.95e-06	9.04e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ERCC2—lung cancer	7.95e-06	9.04e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ABCC3—lung cancer	7.94e-06	9.03e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP2E1—lung cancer	7.92e-06	9e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP2E1—lung cancer	7.85e-06	8.92e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NQO1—lung cancer	7.83e-06	8.9e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCL8—lung cancer	7.82e-06	8.88e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ERBB3—lung cancer	7.77e-06	8.83e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NQO1—lung cancer	7.76e-06	8.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CAT—lung cancer	7.74e-06	8.8e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.69e-06	8.75e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—AKR1C1—lung cancer	7.69e-06	8.74e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—STK11—lung cancer	7.67e-06	8.72e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	7.6e-06	8.64e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	7.53e-06	8.56e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ABCB1—lung cancer	7.53e-06	8.56e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL2—lung cancer	7.47e-06	8.49e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—UGT1A1—lung cancer	7.47e-06	8.49e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TERT—lung cancer	7.44e-06	8.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—TYMS—lung cancer	7.39e-06	8.4e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTM1—lung cancer	7.31e-06	8.31e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—FGFR1—lung cancer	7.23e-06	8.21e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	7.2e-06	8.19e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GNG11—lung cancer	7.2e-06	8.18e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HIF1A—lung cancer	7.12e-06	8.09e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTP1—lung cancer	7.1e-06	8.07e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—STK11—lung cancer	7.06e-06	8.02e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—APOA1—lung cancer	7.02e-06	7.98e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—STK11—lung cancer	7e-06	7.95e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CYP1A1—lung cancer	6.93e-06	7.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CAT—lung cancer	6.91e-06	7.85e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—APOA1—lung cancer	6.88e-06	7.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ERCC2—lung cancer	6.87e-06	7.81e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—APOA1—lung cancer	6.87e-06	7.81e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	6.87e-06	7.81e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ALDOA—lung cancer	6.86e-06	7.79e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—KDR—lung cancer	6.81e-06	7.74e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ABCB1—lung cancer	6.72e-06	7.64e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NCOA3—lung cancer	6.66e-06	7.57e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—TYMS—lung cancer	6.6e-06	7.5e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	6.57e-06	7.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTP1—lung cancer	6.53e-06	7.42e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTM1—lung cancer	6.52e-06	7.41e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ADCY1—lung cancer	6.48e-06	7.36e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ABCG2—lung cancer	6.48e-06	7.36e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTP1—lung cancer	6.47e-06	7.36e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CG—lung cancer	6.41e-06	7.29e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CAT—lung cancer	6.35e-06	7.22e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—HPGDS—lung cancer	6.35e-06	7.22e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ENO2—lung cancer	6.35e-06	7.22e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PPP2R1B—lung cancer	6.31e-06	7.17e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CAT—lung cancer	6.3e-06	7.16e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CG—lung cancer	6.28e-06	7.14e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CG—lung cancer	6.27e-06	7.13e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—KIT—lung cancer	6.27e-06	7.13e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—APC—lung cancer	6.27e-06	7.13e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—NRAS—lung cancer	6.27e-06	7.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	6.26e-06	7.12e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EGF—lung cancer	6.2e-06	7.04e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP1A1—lung cancer	6.18e-06	7.03e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ABCB1—lung cancer	6.18e-06	7.02e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTT1—lung cancer	6.16e-06	7e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ERCC2—lung cancer	6.13e-06	6.97e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ABCB1—lung cancer	6.13e-06	6.96e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—POMC—lung cancer	6.1e-06	6.93e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GCLC—lung cancer	6.09e-06	6.92e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2A6—lung cancer	6.09e-06	6.92e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—TYMS—lung cancer	6.07e-06	6.9e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—TYMS—lung cancer	6.02e-06	6.84e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—MAPK3—lung cancer	6.01e-06	6.83e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTM1—lung cancer	6e-06	6.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—POMC—lung cancer	5.98e-06	6.79e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—POMC—lung cancer	5.97e-06	6.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTM1—lung cancer	5.95e-06	6.76e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—APOA1—lung cancer	5.94e-06	6.76e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CREBBP—lung cancer	5.94e-06	6.75e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—BRAF—lung cancer	5.89e-06	6.7e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL6R—lung cancer	5.82e-06	6.62e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CREBBP—lung cancer	5.82e-06	6.62e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CREBBP—lung cancer	5.81e-06	6.61e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ENO1—lung cancer	5.77e-06	6.56e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—EGFR—lung cancer	5.71e-06	6.49e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.69e-06	6.47e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP1A1—lung cancer	5.69e-06	6.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ERCC2—lung cancer	5.64e-06	6.41e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP1A1—lung cancer	5.64e-06	6.41e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CD—lung cancer	5.64e-06	6.4e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ERCC2—lung cancer	5.59e-06	6.36e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ALB—lung cancer	5.56e-06	6.32e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MAP2K1—lung cancer	5.55e-06	6.31e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CD—lung cancer	5.52e-06	6.27e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CD—lung cancer	5.51e-06	6.27e-05	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—PIK3CA—lung cancer	5.46e-06	6.21e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ALB—lung cancer	5.45e-06	6.19e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CG—lung cancer	5.43e-06	6.17e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—KRAS—lung cancer	5.4e-06	6.13e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—APOA1—lung cancer	5.31e-06	6.03e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2E1—lung cancer	5.18e-06	5.88e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—POMC—lung cancer	5.17e-06	5.87e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NQO1—lung cancer	5.12e-06	5.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.08e-06	5.77e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CREBBP—lung cancer	5.03e-06	5.72e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—PIK3CA—lung cancer	4.96e-06	5.64e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MDM2—lung cancer	4.94e-06	5.61e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—RAF1—lung cancer	4.92e-06	5.59e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CB—lung cancer	4.91e-06	5.58e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—APOA1—lung cancer	4.88e-06	5.55e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ERBB2—lung cancer	4.87e-06	5.53e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PTGS2—lung cancer	4.87e-06	5.53e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CG—lung cancer	4.84e-06	5.51e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—APOA1—lung cancer	4.84e-06	5.5e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CB—lung cancer	4.81e-06	5.47e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CB—lung cancer	4.8e-06	5.46e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MTOR—lung cancer	4.8e-06	5.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CD—lung cancer	4.77e-06	5.42e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PTGS2—lung cancer	4.77e-06	5.42e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ALB—lung cancer	4.71e-06	5.35e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.63e-06	5.27e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCL8—lung cancer	4.62e-06	5.25e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—STK11—lung cancer	4.61e-06	5.24e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—POMC—lung cancer	4.61e-06	5.24e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—HRAS—lung cancer	4.59e-06	5.21e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CREBBP—lung cancer	4.49e-06	5.1e-05	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—AKT1—lung cancer	4.46e-06	5.07e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CG—lung cancer	4.46e-06	5.06e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CASP3—lung cancer	4.42e-06	5.02e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CG—lung cancer	4.42e-06	5.02e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL2—lung cancer	4.41e-06	5.02e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL6—lung cancer	4.39e-06	4.99e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCND1—lung cancer	4.3e-06	4.89e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—JUN—lung cancer	4.29e-06	4.88e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTP1—lung cancer	4.27e-06	4.85e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CD—lung cancer	4.26e-06	4.84e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PTEN—lung cancer	4.24e-06	4.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—POMC—lung cancer	4.24e-06	4.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—POMC—lung cancer	4.2e-06	4.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ALB—lung cancer	4.2e-06	4.78e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MMP9—lung cancer	4.18e-06	4.75e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CDKN1A—lung cancer	4.16e-06	4.73e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CB—lung cancer	4.16e-06	4.73e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PTEN—lung cancer	4.16e-06	4.72e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CAT—lung cancer	4.15e-06	4.72e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PTEN—lung cancer	4.15e-06	4.72e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CREBBP—lung cancer	4.13e-06	4.69e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PTGS2—lung cancer	4.12e-06	4.68e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CREBBP—lung cancer	4.1e-06	4.65e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—AKT1—lung cancer	4.05e-06	4.6e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—EP300—lung cancer	4.05e-06	4.6e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ABCB1—lung cancer	4.04e-06	4.59e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—TYMS—lung cancer	3.97e-06	4.51e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—EP300—lung cancer	3.96e-06	4.51e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EP300—lung cancer	3.96e-06	4.5e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTM1—lung cancer	3.92e-06	4.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CD—lung cancer	3.92e-06	4.45e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CD—lung cancer	3.88e-06	4.41e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ALB—lung cancer	3.87e-06	4.39e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—SRC—lung cancer	3.85e-06	4.38e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ALB—lung cancer	3.83e-06	4.36e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—VEGFA—lung cancer	3.75e-06	4.26e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP1A1—lung cancer	3.72e-06	4.23e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—STAT3—lung cancer	3.71e-06	4.22e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CB—lung cancer	3.71e-06	4.22e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—NRAS—lung cancer	3.7e-06	4.21e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ERCC2—lung cancer	3.69e-06	4.19e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PTGS2—lung cancer	3.68e-06	4.18e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PTEN—lung cancer	3.59e-06	4.08e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MAPK3—lung cancer	3.55e-06	4.03e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MYC—lung cancer	3.45e-06	3.92e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—EP300—lung cancer	3.43e-06	3.89e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CB—lung cancer	3.41e-06	3.88e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CB—lung cancer	3.38e-06	3.85e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PTGS2—lung cancer	3.38e-06	3.84e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EGFR—lung cancer	3.37e-06	3.84e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PTGS2—lung cancer	3.35e-06	3.81e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PTEN—lung cancer	3.21e-06	3.65e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—APOA1—lung cancer	3.19e-06	3.63e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—KRAS—lung cancer	3.19e-06	3.62e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—EP300—lung cancer	3.06e-06	3.48e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PIK3CA—lung cancer	2.99e-06	3.4e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PTEN—lung cancer	2.95e-06	3.35e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PIK3CA—lung cancer	2.93e-06	3.33e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PIK3CA—lung cancer	2.93e-06	3.33e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PTEN—lung cancer	2.92e-06	3.32e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CG—lung cancer	2.91e-06	3.31e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TP53—lung cancer	2.83e-06	3.22e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—EP300—lung cancer	2.81e-06	3.2e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—EP300—lung cancer	2.79e-06	3.17e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—POMC—lung cancer	2.77e-06	3.15e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HRAS—lung cancer	2.71e-06	3.08e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CREBBP—lung cancer	2.7e-06	3.07e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL6—lung cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CD—lung cancer	2.56e-06	2.91e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PIK3CA—lung cancer	2.54e-06	2.88e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ALB—lung cancer	2.53e-06	2.87e-05	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—AKT1—lung cancer	2.45e-06	2.78e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—AKT1—lung cancer	2.4e-06	2.72e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—AKT1—lung cancer	2.39e-06	2.72e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PIK3CA—lung cancer	2.26e-06	2.57e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CB—lung cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PTGS2—lung cancer	2.21e-06	2.51e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PIK3CA—lung cancer	2.08e-06	2.37e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—AKT1—lung cancer	2.07e-06	2.35e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PIK3CA—lung cancer	2.06e-06	2.34e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PTEN—lung cancer	1.93e-06	2.19e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—AKT1—lung cancer	1.85e-06	2.1e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—EP300—lung cancer	1.84e-06	2.09e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—AKT1—lung cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—AKT1—lung cancer	1.69e-06	1.92e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.36e-06	1.55e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—AKT1—lung cancer	1.11e-06	1.26e-05	CbGpPWpGaD
